Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is there someone selling PPHMP and the same person buying PPHM?
Wow - you haven´t forgotten that!
sorry pphmp vol 10280
Wow - 20K bought at 1,49
pphm going up pphmp going down
And as we have seen the past days with the PCYC announcement, the DMC can advice to stop a trial, interim look-in or not, at ANY time they want if the data supports that advice. So these JUMPS can be sudden and as by miracle are traded in PRE-HOURS. What happened to PCYC proves there are leaks at the FDA otherwise you don't jump 7 days to early!
What i´m still missing is: HIGHER VOLUME
there is (was) some money at 1,47 bid - 33k
I thought if this!
MD, I was told that your articel was noticed by some big boys. They bought this week.
Onco from Bayer (but old!)...Nexavar....
ASCO GU 2015 to Feature Latest Oncology Research from Bayer
Includes data from studies evaluating radium-223 dichloride, sorafenib and investigational agent ODM-201
Abstracts: 160, 182, 195, 202, 230, 247, 253, 254, 403
Berlin, February 24, 2015 – Bayer HealthCare announced today that new data from its oncology portfolio will be presented at the 2015 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place February 26 – 28 in Orlando, FL (USA). The presentations will include data on Xofigo® (radium-223 dichloride) and Nexavar® (sorafenib), as well as ODM-201, an investigational therapy Bayer is jointly developing with Orion Corporation.
Notable studies evaluating Bayer's products and pipeline candidates at ASCO GU 2015 are listed below:
Radium-223 Dichloride (radium-223)
1. Effect of radium-223 dichloride (Ra-223) on pain from US EAP
- Abstract 160, Board G22, General Poster Session A: Prostate Cancer
- Thursday, February 26, 11:30 AM – 1:00 PM (EST)
2. External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
- Abstract 182, Board H18, General Poster Session A: Prostate Cancer
- Thursday, February 26, 11:30 AM – 1:00 PM (EST)
3. 3-Year Safety Follow-up of Radium-223 Dichloride (Ra-223) in Patients (Pts) With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (Mets) From ALSYMPCA
- Abstract 195, Board J5, General Poster Session A: Prostate Cancer
- Thursday, February 26, 11:30 AM – 1:00 PM (EST)
4. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial
- Abstract 202, Board J12, General Poster Session A: Prostate Cancer
- Thursday, February 26, 11:30 AM – 1:00 PM (EST)
5. Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP)
- Abstract 247, Board C16, General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
- Friday, February 27, 12:15 – 1:45 PM (EST)
6. Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting
- Abstract 253, Board C22, General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
- Friday, February 27, 12:15 – 1:45 PM (EST)
7. Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel (D) subgroup
- Abstract 254, Board C23, General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
- Friday, February 27, 12:15 – 1:45 PM (EST)
Sorafenib
1. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial
- Abstract 403, Board B1, General Poster Session C: Renal Cell Cancer
- Saturday, February 28, 7:00 AM – 7:55 AM (EST)
ODM-201
1. Pharmacokinetics, activity and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration resistant prostate cancer: An open-label phase I trial with long-term extension
- Abstract 230, Board B24, General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
- Friday, February 27, 12:15 – 1:45 PM (EST)
About Radium-223 Dichloride (Xofigo®)
Radium-223 dichloride (radium-223) is a therapeutic alpha particle-emitting pharmaceutical with an anti-tumor effect on bone metastases. Radium-223 mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. The high linear energy transfer of alpha emitters leads to a high frequency of double-strand DNA breaks in adjacent tumor cells, resulting in a potent cytotoxic effect. The alpha particle range from radium-223 is less than 100 micrometers, which minimizes damage to the surrounding normal tissue.
Radium-223 dichloride has been approved under the brand name Xofigo® in more than 40 countries worldwide, including the U.S. and the EU. In Europe, it is approved for the treatment of adults with CRPC, symptomatic bone metastases and no known visceral metastases.
About Sorafenib (Nexavar®)
Sorafenib, an oral anti-cancer therapy, is approved under the brand name Nexavar® in more than 100 countries worldwide. In Europe, Nexavar is approved for the treatment of hepatocellular carcinoma (HCC); for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy; and for progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
In preclinical studies, sorafenib has been shown to inhibit multiple kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases include Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.
Nexavar is co-developed by Onyx Pharmaceuticals, Inc., an Amgen subsidiary, and Bayer, except in Japan where Bayer manages all development. The companies co-promote Nexavar in the U.S. Outside of the U.S., excluding Japan, Bayer has exclusive marketing rights, and Bayer and Onyx share profits globally.
About ODM-201
ODM-201 is an investigational novel androgen receptor (AR) antagonist with unique chemistry that is designed to block the growth of prostate cancer cells. ODM-201 binds to the AR with high affinity and inhibits receptor function. In nonclinical models, ODM-201 has shown to only minimally penetrate the blood-brain barrier.
In 2014, Bayer and Orion had entered into a global agreement under which they will jointly develop ODM-201, with Bayer contributing a major share of the costs of future development. Bayer will commercialize ODM-201 globally and Orion has the option to co-promote ODM-201 in Europe. Orion will be responsible for the manufacturing of the product.
About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.
Follow us on Facebook: www.facebook.com/healthcare.bayer
Follow us on Twitter: https://twitter.com/BayerHealthCare
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Hmmmm.....not so good for BAYER
Phase III Trial of Regorafenib Shows Insufficient Patient Recruitment
Enrolment will be halted before the study endpoints can be assessed / No new safety signals from study
Berlin, March 5, 2015 – Bayer HealthCare today announced that it is suspending enrolment into a Phase III trial with regorafenib (Stivarga®) in colorectal cancer patients with resected liver metastases due to insufficient patient recruitment. The randomized, double-blind, placebo-controlled Phase III trial is evaluating regorafenib as an adjuvant treatment of colorectal cancer following resection of liver metastases with curative intent. As a result of slow patient accrual, the study will be closed to further enrolment before the study endpoints can be assessed. Importantly, there were no new safety signals from the study.
“We are disappointed that the extensive measures to increase recruitment did not have the desired outcome. We would like to thank the patients and the study investigators for their contributions and participation in this study,” said Dr. Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development. “Importantly, this decision does not affect our commitment for Stivarga in the approved as well as potential additional indications. We will continue to evaluate regorafenib in a number of tumor types with significant unmet medical needs, including colorectal cancer.”
Bayer is informing Health Authorities and investigators on the planned enrolment suspension. The company is actively working with the Data Monitoring Committee, the Study Steering Committee and investigators with regard to the appropriate disposition of patients who have entered into the trial. A summary of the findings will be disclosed to the public as available.
Phase III Trial Design
The COAST (Patients with Stage IV COlorectal Cancer treated with Adjuvant Regorafenib Versus Placebo after Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-controlled Phase-III Study) clinical trial is studying regorafenib in patients with colorectal cancer after curative resection of liver metastases and completion of all planned chemotherapy. The study investigates whether providing 160 mg oral regorafenib in the adjuvant setting increases disease-free survival (DFS) and overall survival (OS) compared to placebo. From the original 750 patients planned to enroll in the study, to date about 25 patients have been enrolled.
About Colorectal Cancer
Colorectal Cancer (CRC) is the third most common cancer worldwide, with over one million cases occurring every year. The five-year survival estimate for CRC on average is 55 percent, but is highly variable dependent on the stage of the disease (from 74 percent for patients with Stage I disease to only 6 percent for Stage IV patients).
About Regorafenib (Stivarga®)
Regorafenib (Stivarga®) is an oral multi-kinase inhibitor that inhibits various kinases within the mechanisms involved in tumor growth and progression – angiogenesis, oncogenesis and the tumor microenvironment. In preclinical studies, regorafenib inhibits several angiogenic VEGF receptor tyrosine kinases that play a role in tumor neoangiogenesis (the growth of new blood vessels). In addition to VEGFR 1-3 it also inhibits various oncogenic and tumor microenvironment kinases including TIE-2, RAF-1, BRAF, BRAFV600, KIT, RET, PDGFR, and FGFR, which individually and collectively impact upon tumor growth, formation of a stromal microenvironment and disease progression.
Regorafenib has been approved under the brand name Stivarga® in more than 70 countries worldwide, including the U.S., Europe and Japan, for the treatment of metastatic colorectal cancer (mCRC). In more than 50 countries worldwide, including the U.S., Europe and Japan, the product has also been approved for the treatment of patients with gastrointestinal stromal tumors (GIST).
Regorafenib is a compound developed by Bayer. In 2011, Bayer entered into an agreement with Onyx Pharmaceuticals, Inc., an Amgen subsidiary, under which Onyx receives a royalty on all global net sales of regorafenib in oncology.
About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 20.0 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.
For mine too - and my clients!
CP, have you seen Euro USD!
Low 1,58 now 1,63
$ 1,63 PM 2k
there is money coming in at 1,46..... nearly all the time
Facebook? We do not use twitter in Europe.
But if its no joke. ....
http://www.roche.com/about/governance/executive_committee/executive_commitee-stephan-feldhaus.htm
But its allways a joke from Sierra. .....
Good joke!
From Bayer to Sanofi....from sorafenib to Docetaxel
http://www.reuters.com/article/2015/02/16/sanofi-bayer-ceo-idUSL5N0VQ30720150216
Eastern Capital - Top 10 Holdings - my latest info:
1.
XOMA Corp XOMA.O
24.37% of portfolio, 6.85m shares +0.55m shares
Latest Filing Date 12-Feb-2014
2.
Portola Pharmaceuticals Inc PTLA.O
20.57% of portfolio, 1.88m shares +0.01m shares
Latest Filing Date 31-Dec-2013
3.
Spectrum Pharmaceuticals Inc SPPI.O
13.85% of portfolio, 4.74m shares +4.74m shares
Latest Filing Date 28-Apr-2014
4.
Cytokinetics Inc CYTK.O
12.09% of portfolio, 2.88m shares +0.50m shares
Latest Filing Date 28-Feb-2014
5.
Ibio Inc IBIO.K
10.38% of portfolio, 21.96m shares Unchanged
Latest Filing Date 10-Nov-2014
6.
Verastem Inc VSTM.O
6.11% of portfolio, 1.97m shares +0.83m shares
Latest Filing Date 30-Jan-2015
7.
Peregrine Pharmaceuticals Inc PPHM.O
5.87% of portfolio, 9.92m shares +2.00m shares
Latest Filing Date 31-Dec-2014
8.
Resverlogix Corp RVX.TO
4.45% of portfolio, 14.97m shares Unchanged
Latest Filing Date 25-Aug-2014
9.
Vericel Corp VCEL.O
1.74% of portfolio, 1.40m shares +0.98m shares
Latest Filing Date 01-Oct-2014
10.
Cyclacel Pharmaceuticals Inc CYCC.O
0.56% of portfolio, 2.11m shares +0.86m shares
Latest Filing Date 12-Feb-2015
If i´m correct than they are searching for Sunrise-patients since April 2014
if you scoll down to " Lungenkrebs (NSCLC, Zweitlinintherapie" ( Lung cancer nsclc...written in green!)
than you get:
Studie für Patienten mit nichtkleinzelligem Lungenkarzinom (NSCLC) im fortgeschrittenen Stadium mit Progress nach einer platinbasierten Chemotherapie bzw. bei bekannter EGFR-Mutation nach einer auf EGFR gerichteten Tyrosinkinasehemmer-Therapie.
Medikamentenstudie (Phase III) mit Docetaxel plus Bavituximab im Vergleich zu Docetaxel plus Placebo
Evangelische Lungenklinik Berlin
.....our SUNRISE!!!!
http://www.pgdiakonie.de/evangelische-lungenklinik-berlin/patientenstudien/
Announcing Keystone Symposia’s
2015 conference on:
Dendritic Cells and
Macrophages Reunited
March 8–13, 2015
Fairmont The Queen Elizabeth
Montreal, Quebec, Canada
TUESDAY, MARCH 10
Mucosal APC
*Julie Magarian Blander, Mount Sinai School of Medicine, USA
Dan R. Littman, HHMI/New York University School of Medicine, USA
Mucosal APC, Th17 and Microbiome
Shigekazu Nagata, Kyoto University, Japan
Exposure of Phosphatidylserine during Apoptosis
Maria Rescigno, European Institute of Oncology, Italy
Mucosal APC and Microbiome
David G. Russell, Cornell University, USA
The Macrophage Plays a Pivotal Role in Mycobacterium tuberculosis
Infections in the Absence and Presence of HIV
Milena Bogunovic, Pennsylvania State University College of
Medicine, USA
Short Talk: Macrophage-Neuronal Crosstalk in Regulating Intestinal
Physiology
The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here?
http://www.thelifesciencesreport.com/pub/na/the-small-cap-biotech-watchlist-2015-unwrapped-who-are-these-guys-and-why-are-they-here
From 2010:
Phosphatidylserine targeting for diagnosis and treatment
of human diseases
http://download.springer.com/static/pdf/528/art%253A10.1007%252Fs10495-010-0503-y.pdf?auth66=1424369744_8a87a209b0d7470302b586ab1812bb4b&ext=.pdf
search for: bavituximab
Market Holiday - Presidents´Day!
Eastern Capital - VERY GOOD!
the link:
http://www.streetinsider.com/SEC+Filings/Form+SC+13GA+PEREGRINE+PHARMACEUTICAL+Filed+by%3A+Eastern+Capital+LTD/10266647.html
BlackRock Institutional Trust Company, N.A.
6.06% 11.03m shares +0.67m shares
Latest Filing Date 31-Dec-2014
Roche acquires Signature Diagnostics to advance translational research for next generation sequencing (NGS) diagnostics
Roche will leverage Signature's unique expertise in both biobanks and NGS assays to develop novel diagnostics for cancer patients
PR Newswire
PLEASANTON, Calif., Feb. 9, 2015
PLEASANTON, Calif., Feb. 9, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the acquisition of Signature Diagnostics AG (Signature), a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung, which are constructed from multicenter prospective clinical studies. Signature uses the samples from its biobanks along with accompanying clinical progression and genetic data to develop and validate circulating cell free DNA (cfDNA) tests1 which have the potential to advance non-invasive treatment response monitoring for patients with cancer.
"Biobanks play an important role in uncovering the cause or origin of disease such as cancer which is important in translational research and the development of personalized therapies for patients," said Roland Diggelmann, COO, Roche Diagnostics. "Signature represents a unique bridge between high value cancer biobanks and NGS assay development. Roche plans to leverage Signature's expertise in both of these areas to accelerate the development of targeted NGS-based diagnostics in the future. Biobanks can also be used for biomarker discovery and hypothesis testing with Pharma."
"We are very pleased Roche recognizes the importance of high-quality longitudinal cancer biobanks for the development of novel NGS-based diagnostics," says Andre Rosenthal, Ph.D. and CEO of Signature. "Joining forces with Roche is very exciting as it will allow us to further develop our NGS assays for sequencing tests using cfDNA which may advance the development of non-invasive treatment response monitoring for cancer patients."
Signature will be integrated into Roche Sequencing Unit and will continue to focus on expanding its innovative genomic signature portfolio.
About Signature
Signature Diagnostics AG is a translational oncology and genomics company based in Potsdam, Germany. Founded in 2004, Signature develops large tumor tissue and plasma biobanks in multiple cancers, including colorectal and lung cancer in the framework of large multicenter prospective clinical studies. A key aspect of the translational oncology work is Signature's biobanks with longitudinal plasma samples from cancer patients. The company also develops several next generation sequencing (NGS) assays using targeted gene panels1. Signature has expertise in developing ultra-deep sequencing tests utilizing cfDNA, which may advance the development of non-invasive treatment response monitoring for cancer patients.
BUZZ-Peregrine Pharmaceuticals Inc: Cancer drug shows promise in animal study
09-Feb-2015 14:35
** Cancer drug developer's shares PPHM.O up 6.56 pct at
$1.30
** Company says combination of its cancer rug, bavituximab, with anti-PD-1 antibody was better at fighting cancer in pre-clinical trials than a anti-PD-1 antibody alone (nMKWlJlv1a)
** Bavituximab, a PS-targeting antibody, blocks cells that suppress the body's immunity to cancer cells, while an anti-PD-1 antibody activates the body's defenses against tumor cells
** Company says data showed the combination treatment reduced by more than 40 pct the number of cells that suppress the immune system from recognizing tumors
** Up to Friday's close, the stock had fallen 12 pct so far this year
PEREGRINE PHARMA PPHM.O UP 7.4 PCT IN PREMARKET TRADING PPHM.O
NEWLY PRESENTED DATA SHOWS THAT PEREGRINE PHARMACEUTICALS' PS-TARGETING ANTIBODIES SIGNIFICANTLY ENHANCE ANTI-TUMOR ACTIVITY OF IMMUNE CHECKPOINT INHIBITORS PD-1 AND CTLA-4 IN MODELS OF BREAST CANCER PPHM.O - RTRS
Proteome Profiling of Breast Cancer Biopsies Reveals a Wound Healing Signature of Cancer-Associated Fibroblasts
http://pubs.acs.org/doi/abs/10.1021/pr500727h
Some cancer news:
Variation in cancer risk among tissues can be explained by the number of stem cell divisions
http://www.sciencemag.org/content/347/6217/78.abstract